A Phase 1/ Phase 2 Study of TTHX1114(NM141)

Completed · Phase 1/Phase 2 · Has a placebo group

Conditions studied: Corneal Endothelial Dystrophy, Fuchs Endothelial Corneal Dystrophy, Pseudophakic Bullous Keratopathy, Endothelial Dysfunction

In brief

Prospective, multicenter, randomized, masked, vehicle-controlled, dose-escalation study

Key facts

Study ID

NCT04520321

Run by

Trefoil Therapeutics, Inc.

People needed

22

Starts

2020-08-19

Expected to finish

2021-05-18

Last updated by the study team

2023-10-30

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• North Bay Eye Associates, Inc. — Petaluma, California, United States
• Levenson Eye Associates, Inc — Jacksonville, Florida, United States
• Chicago Corneal Consultants — Hoffman Estates, Illinois, United States
• Price Vision Group — Indianapolis, Indiana, United States
• Tauber Eye Center — Kansas City, Missouri, United States
• Vance Thompson Vision - Omaha — Omaha, Nebraska, United States
• Alterman, Modi and Wolter — Poughkeepsie, New York, United States
• Vance Thompson Vision - Sioux Falls — Sioux Falls, South Dakota, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.